Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
1.
Asian Journal of Andrology ; (6): 24-29, 2018.
Article Dans Anglais | WPRIM | ID: wpr-1009523

Résumé

Emerging evidence indicates that aldosterone and mineralocorticoid receptors (MRs) are associated with the pathogenesis of erectile dysfunction. However, the molecular mechanisms remain largely unknown. In this study, freshly isolated penile corpus cavernosum tissue from rats was treated with aldosterone, with or without MRs inhibitors. Nuclear factor (NF)-kappa B (NF-κB) activity was evaluated by real-time quantitative PCR, luciferase assay, and immunoblot. The results demonstrated that mRNA levels of the NF-κB target genes, including inhibitor of NF-κB alpha (IκB-α), NF-κB1, tumor necrosis factor-alpha (TNF-α), and interleukin 6 (IL-6), were higher after aldosterone treatment. Accordingly, phosphorylation of p65/RelA, IκB-α, and inhibitor of NF-κB kinase-β was markedly increased by aldosterone. Furthermore, knockdown of MRs prevented activation of the NF-κB canonical pathway by aldosterone. Consistent with this finding, ectopic overexpression of MRs enhanced the transcriptional activation of NF-κB by aldosterone. More importantly, the MRs antagonist, spironolactone blocked aldosterone-mediated activation of the canonical NF-κB pathway. In conclusion, aldosterone has an inflammatory effect in the corpus cavernosum penis, inducing NF-κB activation via an MRs-dependent pathway, which may be prevented by selective MRs antagonists. These data reveal the possible role of aldosterone in erectile dysfunction as well as its potential as a novel pharmacologic target for treatment.


Sujets)
Animaux , Mâle , Rats , Aldostérone/pharmacologie , Cytokines/biosynthèse , Techniques de knock-down de gènes , I-kappa B Kinase/antagonistes et inhibiteurs , Interleukine-6/génétique , Antagonistes des récepteurs des minéralocorticoïdes/pharmacologie , Facteur de transcription NF-kappa B/génétique , Pénis/métabolisme , Protein-Serine-Threonine Kinases/antagonistes et inhibiteurs , ARN messager/biosynthèse , Rats de lignée WKY , Récepteurs des minéralocorticoïdes/génétique , Transduction du signal/effets des médicaments et des substances chimiques , Spironolactone/pharmacologie , Activation de la transcription , Facteur de nécrose tumorale alpha/biosynthèse ,
2.
Acta cir. bras ; 29(11): 696-702, 11/2014. tab, graf
Article Dans Anglais | LILACS | ID: lil-728643

Résumé

PURPOSE: To explore the mechanism of resistance to IKKβ inhibitor in multiple myeloma (MM) cells and uncover novel therapeutic targets for MM. METHODS: We downloaded the microarray data (GSE8476) from GEO (Gene Expression Omnibus) database. The data were derived from the human MM cells lines (L363 cells) treated with IKKβ inhibitor MLN120b (MLN) for eight, 12 and 24 hours. Furthermore, we applied the Search Tool for the Retrieval of Interacting Genes (STRING) and Expression Analysis Systematic Explorer (EASE) database to construct protein-protein interaction networks and identified over-represented pathway among DEGs (differentially expressed genes). RESULTS: We obtained 108 DGEs in 8h vs. 12h group and 101 ones in 8h vs. 24h group. Most of DGEs were found to be involved in biological regulation. The significant pathways were Ig A pathway and the CAMs pathways. In addition, 24 common DGEs were found in the networks of the two groups such as ICAM 3 and SELL. CONCLUSION: Intercellular adhesion molecule 3 and SELL may be potential targets in multiple myeloma treatment in the future. .


Sujets)
Humains , Ciblage de gène/méthodes , I-kappa B Kinase/antagonistes et inhibiteurs , Myélome multiple/traitement médicamenteux , Myélome multiple/génétique , Séquençage par oligonucléotides en batterie/méthodes , Adhérence cellulaire , Lignée cellulaire tumorale , Analyse de regroupements , I-kappa B Kinase/métabolisme , Myélome multiple/métabolisme , Reproductibilité des résultats , Facteurs temps
3.
Experimental & Molecular Medicine ; : 513-520, 2012.
Article Dans Anglais | WPRIM | ID: wpr-192551

Résumé

During ischemia-reperfusion injury, brief pre-exposure to oxidative stress renders organs resistant to subsequent severe damage. NF-kappaB is a transcription factor that is involved in reperfusion-induced inflammatory and immune responses. The activity of NF-kappaB has been shown to be modulated by oxidative stress in various cell types through different pathways. We studied the effect of pre-exposure to oxidative stress on subsequent NF-kappaB activation in TNFalpha-stimulated HEK293 cells. The cells were transiently exposed to 0.5 mM H2O2 for 20 min, prior to stimulation with TNFalpha, and the subsequent expression of NF-kappaB-dependent genes and the levels of NF-kappaB signaling molecules were measured. Pre-exposure to H2O2 significantly delayed the TNFalpha-induced expression of an NF-kappaB reporter gene and inflammatory proteins (intercellular adhesion molecule-1 and IL-1beta). The degradation of inhibitor of NF-kappaB alpha (IkappaBalpha) and the nuclear translocation of NF-kappaB were also delayed by H2O2 treatment, whereas IkappaBalpha phosphorylation and IkappaB kinase activity were not changed. When we examined the ubiquitin/proteosome pathway in H2O2-treated cells, we could not detect significant changes in proteosomal peptidase activities, but we were able to detect a delay of IkappaBalpha poly-ubiquitination. Our results suggest that transient exposure to oxidative stress temporally inhibits NF-kappaB-dependent gene expression by suppressing the poly-ubiquitination of phosphorylated IkappaBalpha in HEK293 cells.


Sujets)
Humains , Transport nucléaire actif , Noyau de la cellule/métabolisme , Activation enzymatique/effets des médicaments et des substances chimiques , Cellules HEK293 , Peroxyde d'hydrogène/pharmacologie , I-kappa B Kinase/antagonistes et inhibiteurs , Phosphorylation/effets des médicaments et des substances chimiques , Transport des protéines , Facteur de nécrose tumorale alpha/pharmacologie , Ubiquitination/effets des médicaments et des substances chimiques
4.
Experimental & Molecular Medicine ; : 277-287, 2009.
Article Dans Anglais | WPRIM | ID: wpr-49339

Résumé

Matrix metalloproteinase-9 (MMP-9) may play an important role in emphysematous change in chronic obstructive pulmonary disease (COPD), one of the leading causes of mortality and morbidity worldwide. We previously reported that simvastatin, an inhibitor of HMG-CoA reductase, attenuates emphysematous change and MMP-9 induction in the lungs of rats exposed to cigarette smoke. However, it remained uncertain how cigarette smoke induced MMP-9 and how simvastatin inhibited cigarette smoke-induced MMP-9 expression in alveolar macrophages (AMs), a major source of MMP-9 in the lungs of COPD patients. Presently, we examined the related signaling for MMP-9 induction and the inhibitory mechanism of simvastatin on MMP-9 induction in AMs exposed to cigarette smoke extract (CSE). In isolated rat AMs, CSE induced MMP-9 expression and phosphorylation of ERK and Akt. A chemical inhibitor of MEK1/2 or PI3K reduced phosphorylation of ERK or Akt, respectively, and also inhibited CSE-mediated MMP-9 induction. Simvastatin reduced CSE-mediated MMP-9 induction, and simvastatin-mediated inhibition was reversed by farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP). Similar to simvastatin, inhibition of FPP transferase or GGPP transferase suppressed CSE-mediated MMP-9 induction. Simvastatin attenuated CSE-mediated activation of RAS and phosphorylation of ERK, Akt, p65, IkappaB, and nuclear AP-1 or NF-kappaB activity. Taken together, these results suggest that simvastatin may inhibit CSE-mediated MMP-9 induction, primarily by blocking prenylation of RAS in the signaling pathways, in which Raf-MEK-ERK, PI3K/Akt, AP-1, and IkappaB-NF-kappaB are involved.


Sujets)
Animaux , Rats , Phosphatidylinositol 3-kinase/métabolisme , Alkyl et aryl transferases/métabolisme , Anticholestérolémiants/pharmacologie , Cellules cultivées , Antienzymes/métabolisme , Extracellular Signal-Regulated MAP Kinases/métabolisme , Régulation de l'expression des gènes codant pour des enzymes/effets des médicaments et des substances chimiques , I-kappa B Kinase/antagonistes et inhibiteurs , Macrophages alvéolaires/cytologie , Matrix metalloproteinase 9/génétique , Mitogen-Activated Protein Kinase Kinases/métabolisme , Polyisoprényl-phosphates/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Sesquiterpènes/métabolisme , Transduction du signal/physiologie , Simvastatine/pharmacologie , Fumée/effets indésirables , Nicotiana/effets indésirables
SÉLECTION CITATIONS
Détails de la recherche